Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAle… Read more
Nymox Pharmaceutical Corporation (NYMXF) - Total Assets
Latest total assets as of December 2023: $627.00K USD
Based on the latest financial reports, Nymox Pharmaceutical Corporation (NYMXF) holds total assets worth $627.00K USD as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nymox Pharmaceutical Corporation - Total Assets Trend (2019–2023)
This chart illustrates how Nymox Pharmaceutical Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nymox Pharmaceutical Corporation - Asset Composition Analysis
Current Asset Composition (December 2023)
Nymox Pharmaceutical Corporation's total assets of $627.00K consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.2% |
| Accounts Receivable | $11.00K | 1.8% |
| Inventory | $16.00K | 2.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Nymox Pharmaceutical Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nymox Pharmaceutical Corporation's current assets represent 99.7% of total assets in 2023, an increase from 87.7% in 2019.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2023, down from 86.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 2.6% of total assets.
Nymox Pharmaceutical Corporation Competitors by Total Assets
Key competitors of Nymox Pharmaceutical Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Nymox Pharmaceutical Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nymox Pharmaceutical Corporation generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nymox Pharmaceutical Corporation is currently not profitable relative to its asset base.
Nymox Pharmaceutical Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.16 | 0.69 | 1.91 |
| Quick Ratio | 0.16 | 0.69 | 1.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.17 Million | $ -650.00K | $ 2.00 Million |
Nymox Pharmaceutical Corporation - Advanced Valuation Insights
This section examines the relationship between Nymox Pharmaceutical Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 48.01 |
| Latest Market Cap to Assets Ratio | 8.45 |
| Asset Growth Rate (YoY) | -61.4% |
| Total Assets | $627.00K |
| Market Capitalization | $5.30 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nymox Pharmaceutical Corporation's assets at a significant premium ( 8.45x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Nymox Pharmaceutical Corporation's assets decreased by 61.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nymox Pharmaceutical Corporation (2019–2023)
The table below shows the annual total assets of Nymox Pharmaceutical Corporation from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $627.00K | -61.42% |
| 2022-12-31 | $1.62 Million | -20.03% |
| 2021-12-31 | $2.03 Million | -58.80% |
| 2020-12-31 | $4.93 Million | -18.85% |
| 2019-12-31 | $6.08 Million | -- |